title: Bioequivalence in the real world is a complex challenge: the case of clopidogrel.
authors.forename: Rossella
authors.initials: R
authors.lastname: Marcucci
authors.forename: Rita
authors.initials: R
authors.lastname: Paniccia
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Gori
authors.forename: Gian Franco
authors.initials: GF
authors.lastname: Gensini
authors.forename: Rosanna
authors.initials: R
authors.lastname: Abbate
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use*; D013810:Therapeutic Equivalency; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine